Patents by Inventor Laird Bloom
Laird Bloom has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240117030Abstract: The present invention relates to antibodies that specifically bind to one or more of IL-4, IL-13, IL-33, TSLP, and p40. The present invention further relates to antibodies that bind to one of IL-4, IL-13, IL-33, or TSLP. The invention further relates to multispecific antibodies that specifically bind to IL-4 and IL-13, and at least one other target. The present invention relates to multispecific antibodies that bind IL-4, IL-13, and one of IL-33, TSLP, or p40. The present invention also pertains to related molecules, e.g. nucleic acids which encode such antibodies or multispecific antibodies, compositions, and related methods, e.g., methods for producing and purifying such antibodies and multispecific antibodies, and their use in diagnostics and therapeutics.Type: ApplicationFiled: February 28, 2023Publication date: April 11, 2024Inventors: Rita Diane AGOSTINELLI, James Reasoner APGAR, Eric Matthew BENNETT, Laird BLOOM, Ting CHEN, Aaron Michael D'ANTONA, Arnab DE, Fang JIN, Marion Teresa KASAIAN, Matthew Allister LAMBERT, Kimberly Ann MARQUETTE, Virginie MCMANUS, Jessica Haewon MIN DEBARTOLO, Nicole Melissa PICHE-NICHOLAS, Richard Thomas SHELDON, Lioudmila TCHISTIAKOVA, Alexander Michael Shuford BARRON, Richard Lee GIESECK, III, Xiaotian ZHONG
-
Publication number: 20240059799Abstract: The present invention discloses an isolated antibody that specifically binds to TL1A, comprising a heavy chain variable region (TL1A-VH) and a light chain variable region (TL1A-VL), comprising the CDR-H1, CDR-H2, and CDR-H3 sequences of a TL1A-VH sequence selected from the group consisting of SEQ ID NO: 42, SEQ ID NO: 44, SEQ ID NO: 47, SEQ ID NO: 49, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 57, SEQ ID NO: 70, SEQ ID NO: 72, SEQ ID NO: 78, SEQ ID NO: 80, SEQ ID NO: 89, SEQ ID NO: 93, SEQ ID NO: 95, SEQ ID NO: 97, SEQ ID NO: 99, SEQ ID NO: 101, SEQ ID NO: 103, SEQ ID NO: 105, SEQ ID NO: 110, SEQ ID NO: 120; and the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 18.Type: ApplicationFiled: May 9, 2023Publication date: February 22, 2024Applicants: Pfizer Inc., Bristol-Myers Squibb CompanyInventors: James Reasoner APGAR, Laird BLOOM, Fang JIN, Fridrik KARLSSON, Kimberly Ann MARQUETTE, Jessica Haewon MIN DEBARTOLO, Nicole Melissa PICHE-NICHOLAS, Lioudmila TCHISTIAKOVA
-
Publication number: 20240052047Abstract: The present invention relates to antibodies that specifically bind to one or both of IL27RA and gp130. The present invention further relates to bispecific antibodies that specifically bind to IL27RA and gp130. The present invention also pertains to related molecules, e.g. nucleic acids which encode such antibodies or bispecific antibodies, compositions, and related methods, e.g.Type: ApplicationFiled: August 1, 2023Publication date: February 15, 2024Inventors: Yijie GAO, Nicholas Andrew MARZE, Laird BLOOM
-
Publication number: 20200308272Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to IL-33, as well as uses, and associated methods thereof.Type: ApplicationFiled: December 29, 2019Publication date: October 1, 2020Inventors: Laird BLOOM, Karl Henry NOCKA, James Reasoner APGAR, Matthew Allister LAMBERT, Mark A. FARMER
-
Patent number: 10544212Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to IL-33, as well as uses, and associated methods thereof.Type: GrantFiled: April 24, 2017Date of Patent: January 28, 2020Assignee: Pfizer Inc.Inventors: Laird Bloom, Karl Henry Nocka, James Reasoner Apgar, Matthew Allister Lambert, Mark A. Farmer
-
Publication number: 20180155452Abstract: Bispecific heterodimeric diabody molecules and uses thereof in the treatment of cancer. The bispecific heterodimeric diabody molecules comprise two polypeptide chains that associate to form two epitope binding sites recognizing the P-cadherin tumor cell associated antigen and the CD3 T cell antigen.Type: ApplicationFiled: December 13, 2017Publication date: June 7, 2018Applicant: Pfizer Inc.Inventors: Chad Michael May, Adam Reid Root, William A. Brady, Lioudmila Gennadievna Tchistiakova, Lidia Mosyak, Laird Bloom, Paul A. Moore, Leslie S. Johnson
-
Publication number: 20180037644Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to IL-33, as well as uses, and associated methods thereof.Type: ApplicationFiled: April 24, 2017Publication date: February 8, 2018Inventors: Laird BLOOM, Karl Henry NOCKA, James Reasoner APGAR, Matthew Allister LAMBERT, Mark A. FARMER
-
Patent number: 9884921Abstract: Bispecific heterodimeric diabody molecules and uses thereof in the treatment of cancer. The bispecific heterodimeric diabody molecules comprise two polypeptide chains that associate to form two epitope binding sites recognizing the P-cadherin tumor cell associated antigen and the CD3 T cell antigen.Type: GrantFiled: June 26, 2015Date of Patent: February 6, 2018Assignee: Pfizer Inc.Inventors: Chad Michael May, Adam Reid Root, William A. Brady, Lioudmila Gennadievna Tchistiakova, Lidia Mosyak, Laird Bloom, Paul A. Moore, Leslie S. Johnson
-
Publication number: 20160207991Abstract: The present invention relates to antibodies that bind brain-derived neurotrophic factor (BDNF). The invention further relates to nucleic acid sequences coding for such antibodies. The present invention also relates to immunoconjugates comprising the antibodies of the invention and pharmaceutical compositions comprising the antibodies and/or the immunoconjugates. The present invention further relates to methods for treating pain and medical uses relating thereto.Type: ApplicationFiled: September 1, 2015Publication date: July 21, 2016Applicant: PFIZER INC.Inventors: Laird Bloom, Qingcong Lin, Heather Hongrong Shih, Ying Sun, Orla Margaret Cunningham, William James Jonathan Finlay
-
Publication number: 20160002357Abstract: Bispecific heterodimeric diabody molecules and uses thereof in the treatment of cancer. The bispecific heterodimeric diabody molecules comprise two polypeptide chains that associate to form two epitope binding sites recognizing the P-cadherin tumor cell associated antigen and the CD3 T cell antigen.Type: ApplicationFiled: June 26, 2015Publication date: January 7, 2016Applicant: PFIZER INC.Inventors: Chad Michael MAY, Adam Reid ROOT, William A. BRADY, Lioudmila Gennadievna TCHISTIAKOVA, Lidia MOSYAK, Laird BLOOM, Paul A. MOORE, Leslie S. JOHNSON
-
Publication number: 20120276102Abstract: The present invention provides binding proteins and antigen-binding fragments thereof, including human antibodies, that specifically bind to the human interleukin-21 receptor (IL-21R), and methods of using them. The binding proteins can act as, e.g., antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used, e.g., in diagnosing, treating, and/or preventing IL-21R-associated disorders, e.g., inflammatory disorders, autoimmune diseases, allergies, transplant rejection, and other immune system disorders.Type: ApplicationFiled: May 14, 2012Publication date: November 1, 2012Applicant: WYETH LLCInventors: Laird BLOOM, Davinder GILL, Yulia VUGMEYSTER, Deborah A. YOUNG, Margot O'TOOLE, Heath M. GUAY, Karissa K. ADKINS, Amy Arlene WEAVER, Sadhana JAIN, Maya ARAI
-
Publication number: 20120264919Abstract: The present invention provides binding proteins and antigen-binding fragments thereof that specifically bind to the human interleukin-21 receptor (IL-21R). The binding proteins can act as, e.g., antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used, e.g., in diagnosing and/or treating IL-21R-associated disorders, e.g., inflammatory disorders, autoimmune diseases, allergies, transplant rejection, cancer, and other immune system disorders.Type: ApplicationFiled: April 23, 2012Publication date: October 18, 2012Applicants: MEDIMMUNE LIMITED, WYETH LLCInventors: Laird BLOOM, Davinder GILL, Yulia VUGMEYSTER, Deborah A. YOUNG, David LOWE, Viia VALGE-ARCHER
-
Publication number: 20120121505Abstract: The present application provides novel binding proteins, including human binding proteins that specifically bind to the human ErbB2.Type: ApplicationFiled: January 12, 2012Publication date: May 17, 2012Inventors: Davinder Singh Gill, Laird Bloom, Maximillian T. Follettie, Fionnuala McAleese, Sreekumar Kodangattil, John Francis DiJoseph, Nitin K. Damle, Peter R. Baum, Peter A. Thompson, John C. Kumer, Alan F. Wahl, Paul A. Algate, Sateesh Kumar Natarajan
-
Patent number: 8178097Abstract: The present invention provides binding proteins and antigen-binding fragments thereof, including human antibodies, that specifically bind to the human interleukin-21 receptor (IL-21R), and methods of using them. The binding proteins can act as, e.g., antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used, e.g., in diagnosing, treating, and/or preventing IL-21R-associated disorders, e.g., inflammatory disorders, autoimmune diseases, allergies, transplant rejection, and other immune system disorders.Type: GrantFiled: May 26, 2009Date of Patent: May 15, 2012Assignee: Wyeth LLCInventors: Laird Bloom, Davinder Gill, Yulia Vugmeyster, Deborah A. Young, Margot O'Toole, Heath M. Guay, Karissa K. Adkins, Amy Arlene Weaver, Sadhana Jain, Maya Arai
-
Patent number: 8163884Abstract: The present invention provides binding proteins and antigen-binding fragments thereof that specifically bind to the human interleukin-21 receptor (IL-21R). The binding proteins can act as, e.g., antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used, e.g., in diagnosing and/or treating IL-21R-associated disorders, e.g., inflammatory disorders, autoimmune diseases, allergies, transplant rejection, cancer, and other immune system disorders.Type: GrantFiled: May 26, 2009Date of Patent: April 24, 2012Assignees: Wyeth LLC, MedImmune LimitedInventors: Laird Bloom, Davinder Gill, Yulia Vugmeyster, Deborah A. Young, David Lowe, Viia Valge-Archer
-
Publication number: 20100124764Abstract: The invention provides polynucleotide vectors and linkers and methods for designing and making single chain variable fragment (“ScFv”) libraries. The invention also provides polynucleotide vectors and linkers and methods for reformatting the ScFv library into Fab and IgG formats for high throughput production and screening.Type: ApplicationFiled: September 25, 2009Publication date: May 20, 2010Applicant: WyethInventors: Simon Evan Hufton, William James Jonathan Finlay, Ian David Broadbent, Laird Bloom
-
Publication number: 20100075329Abstract: The present invention provides human binding proteins and antigen-binding fragments thereof that specifically bind to the human interleukin-21 receptor (IL21R), and uses therefore. The invention further provides methods to predict whether the binding proteins of the invention may take on agonistic activities in vivo and produce a cytokine storm. In addition, the invention provides methods for determining whether an anti-IL21R binding protein is a neutralizing anti-IL21R binding protein, based on the identification of several IL21-responsive genes. The binding proteins can act as, e.g., antagonists of IL21R activity, thereby modulating immune responses in general, and those mediated by IL21R in particular.Type: ApplicationFiled: September 23, 2009Publication date: March 25, 2010Inventors: Margot O'Toole, Yongjing Guo, Renee Ramsey, Laird Bloom
-
Publication number: 20090304590Abstract: The present application provides novel binding proteins, including human binding proteins that specifically bind to the human ErbB2.Type: ApplicationFiled: October 27, 2008Publication date: December 10, 2009Applicants: Wyeth, Trubion Pharmaceuticals, Inc.Inventors: Davinder Singh Gill, Laird Bloom, Maximillian T. Follettie, Fionnuala McAleese, Sreekumar Kodangattil, John Francis DiJoseph, Nitin K. Damle, Peter R. Baum, Peter A. Thompson, John C. Kumer, Alan F. Wahl, Paul A. Algate, Sateesh Kumar Natarajan
-
Publication number: 20090298081Abstract: The present invention provides binding proteins and antigen-binding fragments thereof, including human antibodies, that specifically bind to the human interleukin-21 receptor (IL-21R), and methods of using them. The binding proteins can act as, e.g., antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used, e.g., in diagnosing, treating, and/or preventing IL-21R-associated disorders, e.g., inflammatory disorders, autoimmune diseases, allergies, transplant rejection, and other immune system disorders.Type: ApplicationFiled: May 26, 2009Publication date: December 3, 2009Applicant: WYETHInventors: Laird BLOOM, Davinder GILL, Yulia VUGMEYSTER, Deborah A. YOUNG, Margot O'TOOLE, Heath M. GUAY, Karissa K. ADKINS, Amy Arlene WEAVER, Sadhana JAIN, Maya ARAI
-
Publication number: 20090298167Abstract: The present invention provides binding proteins and antigen-binding fragments thereof that specifically bind to the human interleukin-21 receptor (IL-21R). The binding proteins can act as, e.g., antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used, e.g., in diagnosing and/or treating IL-21R-associated disorders, e.g., inflammatory disorders, autoimmune diseases, allergies, transplant rejection, cancer, and other immune system disorders.Type: ApplicationFiled: May 26, 2009Publication date: December 3, 2009Applicants: WYETH, MEDIMMUNE LIMITEDInventors: Laird BLOOM, Davinder GILL, Yulia VUGMEYSTER, Deborah A. YOUNG, David LOWE, Viia VALGE-ARCHER